Main Article Content
Infections of the urinary system occupy a leading place among nephrology pathology and infectious diseases in general, in particular, constitute a significant proportion of infections multiresistant microorganisms. The topic of this article is devoted to the etiology and the key stages of the pathogenesis of infectious lesions of the urinary system, particularly complicated pyelonephritis, as well as the comparative characteristics of drugs used in the treatment of these patients. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of the combined antimicrobial drug ceftriaxone/sulbactam.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Stamm W.E. Scientific and clinical challenges in the management of urinary tract infections // Am. J. Med. 2002; 113 (1A): 1S-4S.
Пиріг Л.А., Іванов Д.Д. та ін. Нефрологія: національний підручник. — Донецьк: Видавець Заславський О.Ю., 2014. — С. 80-104.
Grabe M., Bjerklund-Johansen T.E. et al. Guidelines on Urologiсal Infections. European Association of Urology, 2013.
Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997 // Vital Health Stat. 13. 1999; 143: 1-39.
Wang S., Shi Y.K., Huang X.B., Ma K., Xu Q.Q., Xiong L.L., Li J.X., Wang X.F. Bacterial culture and drug sensitivity analysis of upper urinary tract calculi complicating with infection // Beijing Da Xue Xue Bao. 2014 Oct 18; 46 (5): 798-801.
Poudyal N., Gyawali N., Gurung R., Bhattarai N.R., Baral R., Khanal B., Shrestha S., Amatya R., Bhattacharya S.K. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli // Nepal Med. Coll. J. 2012 Mar; 14(1): 5-8.
Xin X., Jian L., Xia X., Jia B., Huang W. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections // Ann. Clin. Microbiol. Antimicrob. 2013 Dec 9; 12: 38. doi: 10.1186/1476-0711-12-38.
Rit K., Naha A. In vitro microbial efficacy of sulbactomax: A novel fixed dose combination of ceftriaxone, sulbactum, and ethylenediaminetetraacetic acid against metallo β-lactamases producing strains of non-fermenters // CHRISMED J. Health Res. 2014; 1: 210-1.
Payasi A., Chaudhary M., Gupta A., Dwivedi V.K., Bhatnagar A. Pharmacokinetic study of sulbactomax // J. Toxicol. Sci. 2010 Aug; 35(4): 459-64.
Shrivastava S.M., Singh R., Tariq A., Siddiqui M.R., Yadav J., Negi P.S., Chaudhary M. A novel high performance liquid chromatographic method for simultaneous determination of ceftriaxone and sulbactam in sulbactomax // Int. J. Biomed. Sci. 2009 Mar; 5(1): 37-43.
Peco-Antić A., Paripović D., Buljugić S., Spasojević-Dimitrijeva B., Cvetković M., Laban-Nestorović S., Milosevski-Lomić G. In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis // Srp. Arh. Celok. Lek. 2012 May-Jun; 140 (5–6): 321-5.
Іванов Д.Д., Кушніренко С.В. Клінічний досвід застосування сульбактомаксу при пієлонефриті в дітей // Новини медицини та фармації. — 2010. — 5 (311).
Winberg J., Bergstron T., Jacobsson B. Morbidity, age and sex distribution: recurrences and renal scarring in symptomatic urinary tract infection in childhood // Kidney Int. 1975; 3 (suppl.): S101-S106.
Foxman B., Barlow R., d’Arcy H. et al. Urinary tract infection: estimated incidence and associated costs // Ann. Epidemiol. 2000; 10: 509-515.
Kunin C.M. Urinary tract infections in females // Clin. Infect. Dis. 1994; 18: 1-12.
Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States // Antimicrob. Agents Chemother. 2002 Aug; 46(8): 2540-5.
Karlowsky J.A., Thornsberry C., Jones M.E., Sahm D.F. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin // Clin. Infect. Dis. 2003 Jan 15; 36(2): 183-7.
Gonzalez C.M., Schaeffer A.J. Treatment of urinary tract infection: what’s old, what’s new, and what works // World J. Urol. 1999; 17: 372-382.
Nickel J.K. Management of urinary tract infections: historical perspective and current strategies: part 2 — modern management // J. Urol. 2005; 173: 27-32.
Scholes D., Hooton T.M., Roberts D.L. et al. Risk factors for recurrent urinary tract infection in young women // J. Infect. Dis. 2000; 182: 1177-1182.
Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study // Int. J. Antimicrob. Agents. 2003 Oct; 22 Suppl. 2: 49-52.